Company news

Gain Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2

October 22, 2024

Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

October 14, 2024

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

October 6, 2024

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease

August 28, 2024

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

August 7, 2024

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease

July 8, 2024

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

June 26, 2024

Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

June 24, 2024

Gain Therapeutics Announces Pricing of $11.0 Million Public Offering

June 12, 2024

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024

May 29, 2024

Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update

May 13, 2024

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

April 23, 2024

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

April 7, 2024

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

March 31, 2024

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

March 25, 2024

Gain Therapeutics to Present at Public Ventures Discovery Day

March 14, 2024

Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease

March 4, 2024

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

February 26, 2024

Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight

February 13, 2024

Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

February 5, 2024

Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update

January 30, 2024

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024

January 1, 2024

Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research

December 3, 2023

Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

November 30, 2023

Gain Therapeutics to Participate in AI Driven Drug Discovery Summit

November 28, 2023

Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option

November 23, 2023

Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants

November 20, 2023

Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

November 13, 2023

Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

October 3, 2023

Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023

September 24, 2023

Gain Therapeutics to Present at the Cambridge Healthtech Institute’s 2nd Annual Neurodegeneration Targets Conference

September 19, 2023

Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia

September 11, 2023

Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model

August 27, 2023

Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

August 9, 2023

Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson’s Disease and Movement Disorders®

August 6, 2023

Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference

July 30, 2023

Gain Therapeutics to Present at the Jefferies Healthcare Conference

May 31, 2023

Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update

May 11, 2023

Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease

May 2, 2023

Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer

April 11, 2023

Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting

March 28, 2023

Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update

March 22, 2023

Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders

March 21, 2023

Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program

March 20, 2023

Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference

March 8, 2023

Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium

February 26, 2023

Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update

November 9, 2022

Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer

September 19, 2022

Gain Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Business Update

August 7, 2022

Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update

May 15, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 33 decks. Every deck is listed under its year.